DK3962601T3 - 5-HT2A-agonister til anvendelse til behandling af depression - Google Patents
5-HT2A-agonister til anvendelse til behandling af depression Download PDFInfo
- Publication number
- DK3962601T3 DK3962601T3 DK20808308.9T DK20808308T DK3962601T3 DK 3962601 T3 DK3962601 T3 DK 3962601T3 DK 20808308 T DK20808308 T DK 20808308T DK 3962601 T3 DK3962601 T3 DK 3962601T3
- Authority
- DK
- Denmark
- Prior art keywords
- depression
- treatment
- ht2a agonists
- ht2a
- agonists
- Prior art date
Links
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207578 | 2019-11-07 | ||
| US17/090,457 US11246860B2 (en) | 2019-11-07 | 2020-11-05 | 5-HT2A agonists for use in treatment of depression |
| PCT/EP2020/081357 WO2021089824A1 (en) | 2019-11-07 | 2020-11-06 | 5-ht2a agonists for use in treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3962601T3 true DK3962601T3 (da) | 2023-09-04 |
Family
ID=68502828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20808308.9T DK3962601T3 (da) | 2019-11-07 | 2020-11-06 | 5-HT2A-agonister til anvendelse til behandling af depression |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11246860B2 (da) |
| EP (1) | EP3962601B1 (da) |
| JP (1) | JP2023501275A (da) |
| CN (1) | CN114761083B (da) |
| AU (1) | AU2020379225A1 (da) |
| BR (1) | BR112022008037A2 (da) |
| CA (1) | CA3156513A1 (da) |
| DK (1) | DK3962601T3 (da) |
| ES (1) | ES2953926T3 (da) |
| FI (1) | FI3962601T3 (da) |
| HR (1) | HRP20230856T1 (da) |
| HU (1) | HUE062369T2 (da) |
| IL (1) | IL292585B2 (da) |
| LT (1) | LT3962601T (da) |
| MA (1) | MA55821B1 (da) |
| MD (1) | MD3962601T2 (da) |
| PL (1) | PL3962601T3 (da) |
| PT (1) | PT3962601T (da) |
| SI (1) | SI3962601T1 (da) |
| WO (1) | WO2021089824A1 (da) |
| ZA (1) | ZA202204809B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| CA3177454A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| JP2024519457A (ja) * | 2021-05-06 | 2024-05-14 | ロホラ エペィエス | （ｓ）－３－（２，５－ジメトキシ－４－（トリフルオロメチル）フェニル）ピペリジン及び（ｓ）－３－（２－メトキシ－５－（メチルチオ）－４－（トリフルオロメチル）フェニル）ピペリジンの酸付加塩、その特定の多形並びにそれらの製造方法 |
| IL309842A (en) * | 2021-07-26 | 2024-02-01 | Univ Louisiana State | Compounds and methods for treating situations where the response depends on 5-HT2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314286D0 (en) * | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
-
2020
- 2020-11-05 US US17/090,457 patent/US11246860B2/en active Active
- 2020-11-06 CA CA3156513A patent/CA3156513A1/en active Pending
- 2020-11-06 PT PT208083089T patent/PT3962601T/pt unknown
- 2020-11-06 JP JP2022525596A patent/JP2023501275A/ja active Pending
- 2020-11-06 FI FIEP20808308.9T patent/FI3962601T3/fi active
- 2020-11-06 MA MA55821A patent/MA55821B1/fr unknown
- 2020-11-06 PL PL20808308.9T patent/PL3962601T3/pl unknown
- 2020-11-06 HR HRP20230856TT patent/HRP20230856T1/hr unknown
- 2020-11-06 DK DK20808308.9T patent/DK3962601T3/da active
- 2020-11-06 SI SI202030239T patent/SI3962601T1/sl unknown
- 2020-11-06 LT LTEPPCT/EP2020/081357T patent/LT3962601T/lt unknown
- 2020-11-06 CN CN202080078033.1A patent/CN114761083B/zh active Active
- 2020-11-06 IL IL292585A patent/IL292585B2/en unknown
- 2020-11-06 HU HUE20808308A patent/HUE062369T2/hu unknown
- 2020-11-06 MD MDE20220277T patent/MD3962601T2/ro unknown
- 2020-11-06 WO PCT/EP2020/081357 patent/WO2021089824A1/en active Search and Examination
- 2020-11-06 ES ES20808308T patent/ES2953926T3/es active Active
- 2020-11-06 AU AU2020379225A patent/AU2020379225A1/en active Pending
- 2020-11-06 EP EP20808308.9A patent/EP3962601B1/en active Active
- 2020-11-06 BR BR112022008037A patent/BR112022008037A2/pt unknown
-
2021
- 2021-06-16 US US17/349,255 patent/US11633390B2/en active Active
- 2021-07-06 US US17/368,351 patent/US11642336B2/en active Active
-
2022
- 2022-04-29 ZA ZA2022/04809A patent/ZA202204809B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220062257A1 (en) | 2022-03-03 |
| IL292585B2 (en) | 2023-08-01 |
| US20210330658A1 (en) | 2021-10-28 |
| US11642336B2 (en) | 2023-05-09 |
| ES2953926T3 (es) | 2023-11-17 |
| MD3962601T2 (ro) | 2023-10-31 |
| IL292585A (en) | 2022-06-01 |
| US11633390B2 (en) | 2023-04-25 |
| CN114761083B (zh) | 2024-02-13 |
| JP2023501275A (ja) | 2023-01-18 |
| CN114761083A (zh) | 2022-07-15 |
| SI3962601T1 (sl) | 2023-10-30 |
| ZA202204809B (en) | 2022-11-30 |
| US11246860B2 (en) | 2022-02-15 |
| FI3962601T3 (fi) | 2023-08-09 |
| PT3962601T (pt) | 2023-08-28 |
| MA55821B1 (fr) | 2023-08-31 |
| HUE062369T2 (hu) | 2023-10-28 |
| WO2021089824A1 (en) | 2021-05-14 |
| MA55821A (fr) | 2022-05-04 |
| EP3962601B1 (en) | 2023-05-31 |
| CA3156513A1 (en) | 2021-05-14 |
| LT3962601T (lt) | 2023-09-11 |
| AU2020379225A1 (en) | 2022-05-26 |
| US20210137908A1 (en) | 2021-05-13 |
| BR112022008037A2 (pt) | 2022-07-12 |
| EP3962601A1 (en) | 2022-03-09 |
| PL3962601T3 (pl) | 2023-10-09 |
| HRP20230856T1 (hr) | 2023-11-10 |
| IL292585B1 (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3160234T3 (da) | Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3522904T3 (da) | Flydende sammensætning til anvendelse i behandlingen af gastroesophageal reflux | |
| DK3556383T3 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| DK3570940T3 (da) | Pridopidin til anvendelse i behandling af fragilt x-syndrom | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3506901T3 (da) | Anvendelse af kynurensyre til behandling af muskelatrofi | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3423060T3 (da) | Imatinib til anvendelse til behandling af slagtilfælde | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
| DK3773615T3 (da) | Flydende sammensætning til anvendelse ved behandling af slimhinden i munden-svælget-struben-spiserøret | |
| DK3283064T3 (da) | Derivater til anvendelse i behandling af muskelatrofi | |
| DK3442558T3 (da) | Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis | |
| DK3439641T3 (da) | Sammensætninger, kits og fremgangsmåder til opretholselse af øjenlågshygiejne | |
| DK3242680T3 (da) | Interleukin-1-receptorantagonist til anvendelse i behandling af cystitis | |
| DK3724196T3 (da) | Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551634T3 (da) | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551633T3 (da) | Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3290436T3 (da) | Phenylalanin-fri protein til behandlingen af pku |